Compare Marvell Technology Inc (MRVL) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Tenet Healthcare Corporation — how do they compare? Marvell Technology Inc trades at $279 (market cap $246.84B), while Tenet Healthcare Corporation trades at $260 (market cap $20.98B). The key difference: Marvell Technology Inc is far larger — about 11.8× Tenet Healthcare Corporation's market cap, and Marvell Technology Inc pays a 0.09% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and Tenet Healthcare Corporation for 15 Days on average.
| MRVL | THC | |
|---|---|---|
Market Cap | $246.84B | $20.98B |
Volume | 29,003,830 | 428,008 |
Sector | Technology | Health |
52-Week High | $316.43 | $280.77 |
52-Week Low | $73.73 | $161.37 |
Typical Hold Time | 42 Days | 15 Days |
Enterprise Value | $248.19B | $32.06B |
Dividend Yield | 0.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $284.68, down 0.81% on the day, amid strong bullish technical signals and robust analyst optimism. The stock has delivered consecutive earnings beats, with Q2 2026 EPS of $0.94 exceeding expectations, and is supported by a consensus price target of $327.86. Revenue growth is accelerating, driven by data center demand and custom AI chip deals, though valuation multiples remain elevated with a P/E of 94.26.
The outlook is positive, fueled by AI infrastructure investments and raised fiscal 2028 revenue guidance to $18 billion. Key risks include high valuation sensitivity, competitive pressures, and execution challenges in scaling custom chip production. Analyst consensus is strongly bullish, with 84% buy ratings, but investors should weigh growth prospects against premium pricing and market volatility.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (ROE 53.31%, net margin 9.9%). Recent news highlights strong cash flow supporting capital returns and upcoming Q3 2026 results on October 29. Valuation appears reasonable with P/E of 10.07 and EV/EBITDA of 5.75.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and 7% upside to consensus target of $283.36. Key catalysts include sustained earnings momentum and efficient capital allocation. Risks include surgical volume pressures and cash flow sustainability concerns amid aggressive buybacks. The stock's current technical setup near pivot point $259 suggests balanced risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
